Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBT Margin (2016 - 2025)

Historic EBT Margin for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 86.15%.

  • China Pharma Holdings' EBT Margin rose 154600.0% to 86.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 78.72%, marking a year-over-year increase of 68500.0%. This contributed to the annual value of 104.58% for FY2024, which is 606700.0% down from last year.
  • Latest data reveals that China Pharma Holdings reported EBT Margin of 86.15% as of Q3 2025, which was up 154600.0% from 51.51% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' EBT Margin ranged from a high of 24.28% in Q1 2023 and a low of 155.48% during Q2 2024
  • For the 5-year period, China Pharma Holdings' EBT Margin averaged around 61.34%, with its median value being 54.02% (2023).
  • As far as peak fluctuations go, China Pharma Holdings' EBT Margin crashed by -1014700bps in 2024, and later skyrocketed by 1039700bps in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' EBT Margin stood at 33.94% in 2021, then fell by -28bps to 43.28% in 2022, then tumbled by -32bps to 57.32% in 2023, then crashed by -88bps to 107.98% in 2024, then rose by 20bps to 86.15% in 2025.
  • Its EBT Margin was 86.15% in Q3 2025, compared to 51.51% in Q2 2025 and 69.13% in Q1 2025.